AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34503682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2
Number of subjects: 0
Study 34503682 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 treatment in T-cell-deficient mice
Number of subjects: 0
Study 34503682 — intervention group
Group type: COMPARATOR
Intervention: Genetic ablation of ILC2
Number of subjects: 0
Study 35781083 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed total shoulder arthroplasty (RTSA)
Number of subjects: 124
Study 34105231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge splitting with simultaneous implant placement using patient specific guides (PSGs)
Number of subjects: 20
Study 34105231 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (free hand ridge splitting)
Number of subjects: 20
Study 33691702 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised self-help PR maintenance program
Number of subjects: 144
Study 33691702 — intervention group
Group type: EXPERIMENTAL
Intervention: PR maintenance program
Number of subjects: 144
Study 33691702 — intervention group
Group type: COMPARATOR
Intervention: Control PR group without a maintenance program
Number of subjects: 144
Study 32541548 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism training intervention
Number of subjects: 61
Study 35691565 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone (PMH) use
Number of subjects: 27
Study 35691565 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-only PMH use
Number of subjects: 27
Study 35691565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen-and-progesterone PMH use
Number of subjects: 27
Study 35691565 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 27
Study 35691565 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 27
Study 35691565 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at menopause
Number of subjects: 27
Study 35691565 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) use
Number of subjects: 27
Study 33386201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise (group 1)
Number of subjects: 60
Study 33386201 — intervention group
Group type: COMPARATOR
Intervention: Home exercise (group 2)
Number of subjects: 60
Study 35092845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR, 4.25 h of sleep/night)
Number of subjects: 16
Study 35092845 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep duration (NS, 8.5 h of sleep/night)
Number of subjects: 16
Study 34347860 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg once daily
Number of subjects: 692
Study 34347860 — intervention group
Group type: COMPARATOR
Intervention: Dupilumab 300 mg every other week
Number of subjects: 692
Study 34347860 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 692
Study 34347860 — intervention group
Group type: COMPARATOR
Intervention: Dupilumab
Number of subjects: 692
Study 35749144 — intervention group
Group type: EXPERIMENTAL
Intervention: Helichrysum italicum infusion (HI)
Number of subjects: 27
Study 35749144 — intervention group
Group type: EXPERIMENTAL
Intervention: Helichrysum arenarium infusion (HA)
Number of subjects: 27
Study 35749144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 27
Study 32332617 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (self-management of antihypertensive medication, self-measurement of blood pressure, hypocaloric and low sodium diet, and physical exercise)
Number of subjects: 424
Study 32332617 — intervention group
Group type: COMPARATOR
Intervention: Regular clinical practice (control group)
Number of subjects: 424
Study 35773633 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous running exercise
Number of subjects: 6
Study 35773633 — intervention group
Group type: COMPARATOR
Intervention: Interval running exercise
Number of subjects: 6
Study 35773633 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (both continuous and interval running)
Number of subjects: 6
Study 34418116 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Number of subjects: 50
Study 34418116 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol (in subgroup receiving miglustat)
Number of subjects: 50
Study 34418116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32500599 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan + 5% Dysphania ambrosioides (Group CA5)
Number of subjects: 60
Study 32500599 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan (Group C)
Number of subjects: 60
Study 32500599 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan + 20% Dysphania ambrosioides (Group CA20)
Number of subjects: 60
Study 32500599 — intervention group
Group type: COMPARATOR
Intervention: Control-Blood clot (Group CO)
Number of subjects: 60
Study 36158562 — intervention group
Group type: EXPERIMENTAL
Intervention: m-NMES-LT
Number of subjects: 21
Study 36158562 — intervention group
Group type: COMPARATOR
Intervention: LT
Number of subjects: 21
Study 33340513 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing tutorial group (n = 41)
Number of subjects: 96
Study 33340513 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing tutorial group (n = 37)
Number of subjects: 96
Study 33340513 — intervention group
Group type: COMPARATOR
Intervention: Sitting tutorial group (n = 36)
Number of subjects: 96
Study 33340513 — intervention group
Group type: COMPARATOR
Intervention: Sitting tutorial group (n = 32)
Number of subjects: 96
Study 34085115 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg/day)
Number of subjects: 32
Study 34085115 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan (10 mg/day)
Number of subjects: 32
Study 34085115 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (100 mg/day) with additional PPI (either esomeprazole or vonoprazan)
Number of subjects: 32
Study 33504257 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoregulatory CPP-targets (CPPopt55-15)
Number of subjects: 98
Study 33504257 — intervention group
Group type: COMPARATOR
Intervention: Fixed CPP-targets (CPP within 60-70 mm Hg)
Number of subjects: 98
Study 33504257 — intervention group
Group type: COMPARATOR
Intervention: CPP > 70 mm Hg
Number of subjects: 98
Study 35775210 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth physical activity intervention
Number of subjects: 280
Study 35775210 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported total PA
Number of subjects: 280
Study 35775210 — intervention group
Group type: COMPARATOR
Intervention: Self-help (control) group
Number of subjects: 280
Study 33764445 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 400 μg/m2/day for 5 days via intravenous infusion
Number of subjects: 88
Study 33764445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 33764445 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 88
Study 35459108 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise and nutritional optimization
Number of subjects: 112
Study 35459108 — intervention group
Group type: COMPARATOR
Intervention: Nutritional optimization only
Number of subjects: 112
Study 33768619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg twice daily for 24 weeks
Number of subjects: 60
Study 33768619 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin 550 mg twice daily for 24 weeks
Number of subjects: 60
Study 35798534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (intravenous infusion 6 mg/kg at week 0, followed by subcutaneous injections of 90 mg at week 8 and every 8 weeks)
Number of subjects: 516
Study 35798534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study 35798534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 516
Study 34158031 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) applied to the vastus lateralis for 30 minutes (7s on, 7s off)
Number of subjects: 22
Study 34158031 — intervention group
Group type: COMPARATOR
Intervention: Control group (quiet sitting for 30 minutes)
Number of subjects: 22
Study 34158031 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS)
Number of subjects: 22
Study 32829082 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the ON condition
Number of subjects: 18
Study 32829082 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the OFF condition
Number of subjects: 18
Study 32829082 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS in OCD ON condition
Number of subjects: 18
Study 32829082 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS in OCD OFF condition
Number of subjects: 18
Study 36041126 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC suspension added to the graft (Group 2)
Number of subjects: 24
Study 36041126 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 24
Study 36041126 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestal approach (Group 2)
Number of subjects: 24
Study 36041126 — intervention group
Group type: COMPARATOR
Intervention: Crestal approach (Group 1)
Number of subjects: 24
Study 36041126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach (Group 2)
Number of subjects: 24
Study 36041126 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach (Group 1)
Number of subjects: 24
Study 34335840 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise (12 weeks, 5 times a week)
Number of subjects: 70
Study 34335840 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (12 weeks, 5 times a week)
Number of subjects: 70
Study 34335840 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 70
Study 34335840 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 70
Study 33837986 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery training (20 minutes additional training)
Number of subjects: 32
Study 32442026 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education Program (BEP) using apron and Disaster Evacuation Baby Carrier (DEBC)
Number of subjects: 74
Study 32442026 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study 35943745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.1 mg/kg)
Number of subjects: 384
Study 35943745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2.0 μg/kg)
Number of subjects: 384
Study 35943745 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.9%)
Number of subjects: 384
Study 34385543 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab and pomalidomide combination therapy
Number of subjects: 0
Study 34385543 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab monotherapy
Number of subjects: 0
Study 34385543 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus pomalidomide with dexamethasone
Number of subjects: 0
Study 34385543 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab
Number of subjects: 0
Study 32723399 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 0
Study 32723399 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 0
Study 32723399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35863984 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anesthesia (sevoflurane or desflurane)
Number of subjects: 524
Study 35863984 — intervention group
Group type: COMPARATOR
Intervention: Propofol‐based total intravenous anesthesia (TIVA)
Number of subjects: 524
Study 32684486 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (FO, 6 g fish oil, 3.85 g EPA & DHA)
Number of subjects: 15
Study 32684486 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil + fish oil (COFO, 18.65 g coconut oil, 15 g MCSFA + 6 g fish oil, 3.85 g EPA & DHA)
Number of subjects: 15
Study 32684486 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil (CO, 18.65 g coconut oil, 15 g MCSFA)
Number of subjects: 15
Study 32684486 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (FO)
Number of subjects: 15
Study 32684486 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil + fish oil (COFO)
Number of subjects: 15
Study 33334564 — intervention group
Group type: EXPERIMENTAL
Intervention: Climate Schools-Combined intervention
Number of subjects: 6386
Study 33334564 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6386
Study 34952780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-transformative life-skills education cum sports coaching program
Number of subjects: 853
Study 34975377 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hz rTMS with wrist-ankle acupuncture
Number of subjects: 25
Study 34975377 — intervention group
Group type: COMPARATOR
Intervention: 5-Hz rTMS
Number of subjects: 25
Study 34849603 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported pain
Number of subjects: 126
Study 34849603 — intervention group
Group type: EXPERIMENTAL
Intervention: US-modified CASPAR
Number of subjects: 126
Study 34849603 — intervention group
Group type: COMPARATOR
Intervention: Conventional CASPAR
Number of subjects: 126
Study 34849603 — intervention group
Group type: COMPARATOR
Intervention: US-only criteria
Number of subjects: 126
Study 34849603 — intervention group
Group type: COMPARATOR
Intervention: Screening questionnaires
Number of subjects: 126
Study 34061883 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment delivered by multidisciplinary teams at opioid agonist treatment clinics or community care centers, including on-site testing for HCV, liver fibrosis assessment, counseling, treatment, and posttreatment follow-up.
Number of subjects: 298
Study 34061883 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment delivered in hospital outpatient clinics.
Number of subjects: 298
Study 35120873 — intervention group
Group type: EXPERIMENTAL
Intervention: Design A (distance zone [DZ] 1.5 mm / add 3.0 D)
Number of subjects: 17
Study 35120873 — intervention group
Group type: EXPERIMENTAL
Intervention: Design B (DZ 1.5 mm / add 1.5 D)
Number of subjects: 17
Study 35120873 — intervention group
Group type: EXPERIMENTAL
Intervention: Design C (DZ 3.0 mm / add 3.0 D)
Number of subjects: 17
Study 35120873 — intervention group
Group type: EXPERIMENTAL
Intervention: Design D (DZ 3.0 mm / add 1.5 D)
Number of subjects: 17
Study 35120873 — intervention group
Group type: EXPERIMENTAL
Intervention: All MFGPCL designs
Number of subjects: 17
Study 34611040 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic differential diagnostic support (EDS) used early in the diagnostic process
Number of subjects: 190
Study 34611040 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic differential diagnostic support (EDS) used late in the diagnostic process
Number of subjects: 190
Study 32872011 — intervention group
Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion combined with acupressure
Number of subjects: 0
Study 32872011 — intervention group
Group type: COMPARATOR
Intervention: Pure thunder-fire moxibustion
Number of subjects: 0
Study 34590334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ghrelin infusion (3 µg/kg loading dose followed by 16.9 ng/kg/min continuous infusion)
Number of subjects: 0
Study 34590334 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study 34187120 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ program (12 weeks, 3 times/week)
Number of subjects: 59
Study 34187120 — intervention group
Group type: COMPARATOR
Intervention: Regular training programs (Control)
Number of subjects: 59
Study 33538417 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring + reversal of neuromuscular blockade (M+R)
Number of subjects: 2084
Study 33538417 — intervention group
Group type: COMPARATOR
Intervention: No monitoring nor reversal (noM+noR)
Number of subjects: 2084
Study 33538417 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine reversal
Number of subjects: 2084
Study 33538417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex reversal
Number of subjects: 2084
Study 32199243 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Learning Materials (DLMs)
Number of subjects: 0
Study 32199243 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face training
Number of subjects: 0
Study 36161968 — intervention group
Group type: COMPARATOR
Intervention: Standard condition (standard elicitation of barriers)
Number of subjects: 253
Study 36161968 — intervention group
Group type: EXPERIMENTAL
Intervention: Impossible condition (elicitation using alternative words)
Number of subjects: 253
Study 36161968 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive condition (motivation held constant by the use of a hypothetical incentive)
Number of subjects: 253
Study 36161968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette condition (participants were primed with a vignette)
Number of subjects: 253
Study 33346093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) blood volume (BV) changes
Number of subjects: 32
Study 34883036 — intervention group
Group type: EXPERIMENTAL
Intervention: LymphAssist IPC regimen
Number of subjects: 40
Study 34883036 — intervention group
Group type: COMPARATOR
Intervention: Sequential IPC regimen
Number of subjects: 40
Study 34883036 — intervention group
Group type: COMPARATOR
Intervention: Both groups (LymphAssist and Sequential IPC)
Number of subjects: 40
Study 34883036 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC (both regimens)
Number of subjects: 40
Study 34863622 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural block (CEB) with GA, 0.2% ropivacaine 1 ml/kg (n=25)
Number of subjects: 50
Study 34863622 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia without CEB (n=25)
Number of subjects: 50
Study 34863622 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural block (CEB)
Number of subjects: 50
Study 34863622 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia without CEB
Number of subjects: 50
Study 34863622 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative fentanyl consumption
Number of subjects: 50
Study 32074419 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention involving home visits by trained community health workers for blood-pressure monitoring and counseling, training of physicians, and care coordination in the public sector.
Number of subjects: 2645
Study 32074419 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 2645
Study 32074419 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention.
Number of subjects: 2645
Study 35777410 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month PrEP dispensing plus interim blood-based HIVST (with biannual clinic visits)
Number of subjects: 495
Study 35777410 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month PrEP dispensing plus interim oral fluid-based HIVST (with biannual clinic visits)
Number of subjects: 495
Study 35777410 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (3-month PrEP dispensing with quarterly clinic visits)
Number of subjects: 495
Study 33979838 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal prepregnancy overweight or obese status
Number of subjects: 405
Study 33979838 — intervention group
Group type: COMPARATOR
Intervention: Maternal iron status
Number of subjects: 405
Study 33979838 — intervention group
Group type: COMPARATOR
Intervention: Neonatal iron status
Number of subjects: 405
Study 36164947 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (300 mg/month, min-max=150-1200 mg)
Number of subjects: 202
Study 36164947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg/month for 2 patients with EGPA)
Number of subjects: 202
Study 36164947 — intervention group
Group type: COMPARATOR
Intervention: Mepolizumab
Number of subjects: 202
Study 36164947 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab
Number of subjects: 202
Study 36164947 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological treatment interruption
Number of subjects: 202
Study 36164947 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of biological use
Number of subjects: 202
Study 34051124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 6263
Study 34051124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study 34779658 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 33822368 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with lenalidomide and dexamethasone (D‐Rd)
Number of subjects: 0
Study 33822368 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0
Study 32901243 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing‐containing hydrogen peroxide (5% potassium nitrate)
Number of subjects: 60
Study 32901243 — intervention group
Group type: COMPARATOR
Intervention: Desensitizing‐free hydrogen peroxide (35%)
Number of subjects: 60
Study 33751636 — intervention group
Group type: COMPARATOR
Intervention: SNP-testing procedure for binary clinical outcomes
Number of subjects: 0
Study 34230150 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with TIP (cisplatin, ifosfamide, paclitaxel)
Number of subjects: 12
Study 34230150 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with TIP (cisplatin, ifosfamide, paclitaxel) followed by total mesometrial resection (TMMR) and adjuvant chemotherapy (ACT)
Number of subjects: 12
Study 35604179 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-made acne prescription taken orally
Number of subjects: 20
Study 35604179 — intervention group
Group type: COMPARATOR
Intervention: Chinese patent medicine Qingre Anchuang taken orally (Control)
Number of subjects: 20
Study 33694196 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75%
Number of subjects: 0
Study 33694196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 0